{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:43:25Z","timestamp":1789706605289,"version":"4.0.1"},"reference-count":46,"publisher":"SAGE Publications","issue":"5-6","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    Acute liver injury (ALI) is a recognized adverse event with adeno-associated virus (AAV)-based gene therapies, including delandistrogene moxeparvovec, an AAVrh74-based gene therapy for Duchenne muscular dystrophy. Progression of ALI to acute liver failure (ALF) is rare. In clinical trials, ALF was defined as an international normalized ratio \u22651.5 with encephalopathy and\/or ascites, occurring &lt;26 weeks since product\/treatment exposure, and in the absence of identified preexisting liver disease as assessed by the treating investigator. The two cases presented here represent the only known instances of ALF following delandistrogene moxeparvovec to date, both resulting in fatal outcomes. Both cases occurred in nonambulatory patients (ages 15 and 16 years). Both patients exhibited abrupt elevations in aminotransferases from baseline approximately 4 weeks after delandistrogene moxeparvovec administration. Over the subsequent weeks and despite interventions, aminotransferases, including gamma-glutamyl transferase (GGT), declined concurrently with a continued rise in total bilirubin, consistent with severe hepatocellular injury and a harbinger of ALF. An interdisciplinary expert panel was convened and concluded that no single biomarker or clinical feature consistently predicted the rapid progression of severe ALI to ALF. Advisors recommended basing treatment intervention for severe ALI on the rate and magnitude of changes from baseline in liver biomarkers (\n                    <jats:italic toggle=\"yes\">e.g.,<\/jats:italic>\n                    2\u20133\u00d7 increase in alanine aminotransferase within \u22641 week). For these severe cases, most advisors recommended intravenous methylprednisolone as the initial treatment whereas typical ALI may be managed with oral corticosteroid adjustment or may resolve with time, as seen in the clinical trial experience. Advisors hypothesized that delandistrogene moxeparvovec-related ALI is T-cell-mediated and discussed the potential of additional immunosuppression. Advisors also recommended enhancing baseline evaluation for hepatic comorbidities with lipid profiling, transient elastography, and abdominal ultrasound to further study potential risk factors for ALI progressing to ALF. Finally, there was strong support for generating additional real-world evidence and conducting prospective clinical trials to inform clinical management of ALI in practice.\n                  <\/jats:p>","DOI":"10.1177\/10430342261423168","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:41:41Z","timestamp":1770961301000},"page":"262-279","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management"],"prefix":"10.1177","volume":"37","author":[{"given":"Perry B.","family":"Shieh","sequence":"first","affiliation":[{"name":"University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Proud","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of The King\u2019s Daughters, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1904-5351","authenticated-orcid":false,"given":"Tamir","family":"Diamond","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Chapin","sequence":"additional","affiliation":[{"name":"Ann &amp; Robert H. Lurie Children\u2019s Hospital, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten G.","family":"B\u00f6nnemann","sequence":"additional","affiliation":[{"name":"National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Soslow","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Powell Gene Therapy Center, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[{"name":"Arkansas Children\u2019s Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Brandsema","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Matesanz","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gerber","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara E.","family":"Godwin Wild","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Mason","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Asher","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California Davis Health, Sacramento, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"US Food and Drug Administration. ELEVIDYS\u00ae highlights of prescribing information. 2025. Available from: https:\/\/www.elevidyshcp.com\/pi [Last accessed: December22 2025]."},{"key":"e_1_3_4_3_2","unstructured":"UAE Ministry of Health and Prevention. Registered medical product directory. Available from: https:\/\/mohap.gov.ae\/en\/registered-medical-product-directory [Last accessed: March6 2025]."},{"key":"e_1_3_4_4_2","unstructured":"Qatar Ministry of Public Health. Qatar national formulary. Available from: https:\/\/www.moph.gov.qa\/english\/OurServices\/advancedsearch\/Pages\/servicesdetails.aspx?serviceId=234 [Last accessed: March6 2025]."},{"key":"e_1_3_4_5_2","unstructured":"NHRA Bahrain. Pharmacy & pharmaceutical products regulation (PPR). Available from: https:\/\/www.nhra.bh\/Departments\/PPR\/ [Last accessed: March6 2025]."},{"key":"e_1_3_4_6_2","unstructured":"Oman Ministry of Health. List of registered pharmaceutical manufacturers and products. Available from: https:\/\/moh.gov.om\/en\/hospitals-directorates\/directorates-and-centers-at-hq\/drug-safety-center\/#Resources [Last accessed: March6 2025]."},{"key":"e_1_3_4_7_2","unstructured":"Kuwait Ministry of Health. Drug and dietary supplement price list. Available from: https:\/\/e.gov.kw\/sites\/kgoenglish\/Pages\/eServices\/MOH\/DrugFoodSupplementPrices.aspx [Last accessed: March6 2025]."},{"key":"e_1_3_4_8_2","unstructured":"Ministry of Health Israel. The Israeli drug registry. Available from: https:\/\/israeldrugs.health.gov.il\/#!\/byDrug [Last accessed: March6 2025]."},{"key":"e_1_3_4_9_2","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\u2014Anvisa. Anvisa aprova registro de primeiro produto de terapia g\u00eanica para Distrofia Muscular de Duchenne (DMD). Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2024\/anvisa-aprova-registro-de-primeiro-produto-de-terapia-genica-para-distrofia-muscular-de-duchenne-dmd [Last accessed: March21 2025]."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-45"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300027"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725469"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.01.003"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27955"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26755"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"e_1_3_4_19_2","unstructured":"Goedeker NL Aqul AA Butterfield RJ et al. Management of patients following investigational delandistrogene moxeparvovec gene therapy for duchenne muscular dystrophy: Delphi panel consensus considerations based on clinical trial experience. Presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy 2023. Los Angeles CA USA. 2023."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84077-w"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230185"},{"key":"e_1_3_4_22_2","unstructured":"Mendell JR McDonald CM Mercuri E et al. Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: Phase 1 to phase 3 clinical trials. Presented at 2025 Muscular Dystrophy Association Clinical & Scientific Conference. Dallas TX. 2025."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.11.005"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16065"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.029"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003268"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.12.051"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.7.2835-2842.1992"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021381"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.683"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208937"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00313-7"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.016"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","unstructured":"Gonzalez Castillo Z Aqul AA Hassan S et al. 615P Liver injury after gene therapy in Duchenne muscular dystrophy: A case report and clinical perspective on screening and management. Presented at World Muscle Society. Vienna Austria. 2025.","DOI":"10.1016\/j.nmd.2025.106149"},{"key":"e_1_3_4_36_2","unstructured":"East L Mason S Darton E et al. Model-based evaluation of delandistrogene moxeparvovec adeno-associated virus pharmacokinetics and safety implications. Presented at the ASCPT Annual Meeting. Washington DC. 2025."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.102143"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010253"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.022"},{"key":"e_1_3_4_40_2","unstructured":"Cardon M. Managing acute liver injury & hyperbilirubinemia following delandistrogene moxeparvovec-rokl treatment with intravenous methylprednisolone & ursodiol. Presented at 2025 Muscular Dystrophy Association Clinical & Scientific Conference. Dallas TX. 2025."},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146546"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214084"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2025.09.003"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.01.011"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040727"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666666"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.05.044"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10430342261423168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10430342261423168","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10430342261423168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:10:50Z","timestamp":1787310650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10430342261423168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":46,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1177\/10430342261423168"],"URL":"https:\/\/doi.org\/10.1177\/10430342261423168","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}